Elizabeth Jungman directs Pew’s work on public health, overseeing Pew’s initiatives related to antibiotics and innovation, drug safety, and prescription drug abuse.
Before joining Pew, she served as a senior health policy adviser with the Senate Committee on Health, Education, Labor, and Pensions, where she played a key role in drafting and negotiating the Food and Drug Administration Safety and Innovation Act of 2012, the FDA provisions in the Pandemic All-Hazards Preparedness Reauthorization Act of 2013, and the Drug Quality and Security Act of 2013, which included drug compounding and supply chain security measures.
Before moving to the Hill, Jungman was in private legal practice, where she counseled clients on a broad range of FDA regulatory matters and other health care issues related to the human pharmaceutical industry. She has an undergraduate biology degree from Harvard College, a J.D. from Georgetown University, and a master’s degree in public health from Johns Hopkins University.
Recent WorkView All
Fourteen people—including former pharmacists, pharmacy technicians, and the owners of the New England Compounding Center in Framingham, Massachusetts—were charged Dec. 17 for their alleged roles in a 2012 outbreak of spinal meningitis that sickened more than 750 people and killed 64. Contamination of compounded steroid injections led to a recall of all the company’s products in... Read More
While the threat of antibiotic resistance is growing, regulatory approval for drugs to treat highly resistant bacterial infections can be challenging. Only a small number of patients who contract such infections meet the requirements to participate in traditional clinical trials. It’s difficult for researchers to select and enroll subjects in clinical trials to study treatments for some of... Read More
On Dec. 10, 2014, Senators Michael Bennet (D-CO) and Orrin Hatch (R-UT) introduced a bill to promote the development of much-needed antibiotics. Read More